

Anatara Lifesciences Ltd

Appendix 4D

Half-year Report

31 December 2016

Name of entity
Anatara Lifesciences Ltd

ABN or equivalent company
reference

ACN 145 239 872

Half-year

31 December 2016
(Previous corresponding period: 31
December 2015)

Results for announcement to the market

				\$
Revenue from ordinary activities	Up	2.9%	to	166,423
Net loss after tax (from ordinary activities) for the period attributable to members	Down	65.9%	to	402,285
Net loss for the period attributable to members	Down	65.9%	to	402,285
		31 December 2016		31 December 2015
Net tangible assets		13,212,354		12,834,784
No. of shares		49,413,236		49,338,236
Net asset backing (per share)		0.27		0.26

Distributions

	Amount per security	Franked amount per security
Interim dividend (per share)	-	-
Final dividend (per share)	-	-
Franking	-	-

Explanation of results

Refer to the Directors' Report - Review of Operations.

Changes in controlled entities

N/A

Other information required by Listing Rule 4.2A

N/A

For personal use only

Anatara Lifesciences Ltd

ACN 145 239 872

**Interim report
for the half-year 31 December 2016**

Anatara Lifesciences Ltd ACN 145 239 872
Interim report - 31 December 2016

Contents

	Page
Directors' report	1
Auditor's Independence Declaration	3
Interim financial statements	
Consolidated statement of profit or loss and other comprehensive income	4
Consolidated balance sheet	5
Consolidated statement of changes in equity	6
Consolidated statement of cash flows	7
Notes to the consolidated financial statements	8
Directors' declaration	12
Independent auditor's review report to the members	13
Corporate directory	15

For personal use only

Directors' report

Your directors present their report on the consolidated entity (referred to hereafter as the Group) consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year 31 December 2016.

Directors

The following persons held office as directors of Anatara Lifesciences Ltd during the financial period:

Dr Melvyn Bridges
Mr Iain Ross
Dr Jay Hetzel
Dr Tracie Ramsdale
Mr Paul Grujic
Dr Paul Schober (resigned 23 September 2016)

Principal activities

Dividends

No dividends have been paid during the financial period. The directors do not recommend that a dividend be paid in respect of the interim financial period (2015: \$nil).

Review of operations and financial results

The company continued to expend monies in furthering its effort in developing a non-antibiotic therapy and as a result shows a loss after tax of \$402,285 for the interim period (2015: \$1,179,181).

During the half year to 31 December 2016, the Company made significant progress in continuing to transition Anatara's lead program, Detach™ towards commercialisation in livestock, starting with pigs, and importantly this year with advancing human applications for the technology.

Under the guidance of Co-Founder and Chief Scientific Officer, Dr Tracey Mynott, Anatara has now completed several successful trials on Australian commercial pig farms. Through trials, Detach™ continues to reduce the incidence and severity of diarrhoea, demonstrating an almost 50% reduction in mortality among young pigs, whilst increasing the average weight of piglets at time of weaning. These improvements have the ability to make a significant impact on animal health and reduce the use of antibiotics.

Our pivotal Target Animal Safety (TAS) study was completed for Detach™ and announced to the ASX in September 2016. The study demonstrated that Detach™ was safe for pigs, even when administered at much higher doses and more frequently than recommended. Data from this study reinforces Anatara's pre-existing large safety database.

The TAS study was conducted according to the VICH guidelines, the highest international standard of major commercial territories and may reduce the need for separate TAS studies in each global jurisdiction where product registration is needed. Long term, this strategy presents the most efficient and cost effective way to prepare for the global roll out of Detach™.

The six months to December were critical for Anatara as the Company submitted its application to the Australian Pesticides and Veterinary Medicines Authority (APVMA) to request marketing approval for its lead product, Detach™. The dossier application was a clear, primary point of focus and one which brought to a close over two years of considerable effort from the whole team. The strong application which supports the use of Detach™ as an alternative to the mass use of antibiotics to control diarrhoea in livestock production - in this case, in pigs, was submitted on 4th October 2016 and brings the Company closer to market launch in Australia. Approval in Australia will pave the way for approval and launch in a number of key Asian countries.

The appointment in 2016 of Dr Michael West as Chief Operating Officer, has been of great benefit in readying Anatara for commercial supply. With Dr West's input, the Company produced the necessary manufacturing documentation for the APVMA registration and now has the ability to reproducibly manufacture commercial scale batches of Detach™. In addition to Dr West's appointment, the Anatara team has been further expanded in preparation for the roll-out of Detach™ and pipeline expansion into human indications.

Review of operations and financial results (continued)

Zoetis licensing option

A very pleasing start to the 2016 calendar year came via the significant announcement that the Company had entered into an exclusive agreement with leading global animal health company, Zoetis Inc.

Under the agreement, Zoetis has the exclusive right to evaluate the potential applications of Detach™ for veterinary use in food production animals in all countries aside from Australia and New Zealand. As the world's largest international animal health company, Zoetis has access to substantial research resources and facilities.

Discussions were held during the period with Zoetis researchers at their facilities in the USA, who after receiving material (announced 1st April 2016), began an aggressive Detach™ evaluation program. Milestone payments were announced prior to the period under review, on 1st April 2016 and then post the half year, on 30th January 2017. The milestone payments assisted Anatara with retaining a strong balance sheet during the period.

Importantly, under the evaluation agreement with Zoetis, Anatara retains rights to all intellectual property protecting its technology. In this context, it should be noted that the Company has applied for two new patents covering both the formulation and active ingredient.

Commercial focus

Anatara's initial focus remains on the pork industry globally, however, with the pending Australian APVMA registration, the team is increasingly focussing on pursuing lucrative human applications for our technology.

Following the submission of the APVMA registration application for Detach™, the Anatara team turned its attention to planning for the direct roll-out of Detach™ in Australia and New Zealand, and to further progressing the Company's pipeline of novel products, including products focused on the treatment of gastrointestinal diseases in humans.

During the period, Anatara continued a research and development collaboration with The La Trobe Institute for Molecular Science at La Trobe University (Melbourne) to explore the potential of the active components within Detach™ for the treatment of gastrointestinal diseases in humans.

R&D tax refund

In October 2016, Anatara received \$420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. The company expects a further cash tax rebate this financial year.

Significant changes in the state of affairs

There have been no significant changes in the state of affairs of the Group during the period.

Matters subsequent to the end of the financial year

No matter or circumstance has arisen since 31 December 2016 that has significantly affected, or may significantly affect:

- (a) the Group's operations in future financial periods, or
- (b) the results of those operations in future financial periods, or
- (c) the Group's state of affairs in future financial periods.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 3.

This report is made in accordance with a resolution of directors.



Mel Bridges
Executive Chairman

Brisbane, Queensland

Dated: This the 22th Day of February 2017.

The Rialto, Level 30
525 Collins St
Melbourne Victoria 3000

Correspondence to:
GPO Box 4736
Melbourne Victoria 3001

T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au

Auditor's Independence Declaration
To The Directors of Anantara Lifesciences Ltd

In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Anantara Lifesciences Ltd for the half-year ended 31 December 2016, I declare that, to the best of my knowledge and belief, there have been:

- a No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b No contraventions of any applicable code of professional conduct in relation to the review.



GRANT THORNTON AUDIT PTY LTD
Chartered Accountants



M A Cunningham
Partner - Audit & Assurance

Melbourne, 22 February 2017

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

For personal use only

Anatara Lifesciences Ltd
Consolidated statement of profit or loss and other comprehensive income
For the half-year 31 December 2016

	Notes	31 December 2016 \$	31 December 2015 \$
Interest received	7	166,423	161,766
Other income - R&D tax incentive	7	1,936,105	165,246
Expenses from operating activities			
Depreciation and amortisation expense		(6,357)	-
Research and development expenses		(773,554)	(338,763)
Patent expenses		(59,897)	(73,178)
Consultancy expenses		(331,124)	(337,729)
Staff expenses		(1,010,649)	(500,058)
Travel and accommodation		(137,189)	(130,151)
ASX and share registry fees		(55,617)	(55,928)
Other expenses		(130,426)	(70,386)
Loss before income tax		(402,285)	(1,179,181)
Income tax expense		-	-
Loss for the period		(402,285)	(1,179,181)
Other comprehensive income for the period, net of tax		-	-
Total comprehensive loss for the period		(402,285)	(1,179,181)
		Cents	Cents
Loss per share:			
Basic loss per share	8	(0.81)	(2.76)
Diluted loss per share	8	(0.81)	(2.76)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

For personal use only

Anatara Lifesciences Ltd
Consolidated balance sheet
As at 31 December 2016

	31 December 2016	30 June 2016
Notes	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	5,913,493	6,387,041
Other receivables	1,591,017	60,272
Financial assets - term deposits	5,855,460	7,437,669
Other current assets - prepayments	113,835	18,720
Total current assets	13,473,805	13,903,702
Non-current assets		
Property, plant and equipment	19,322	16,259
Other non-current assets	11,400	-
Total non-current assets	30,722	16,259
Total assets	13,504,527	13,919,961
LIABILITIES		
Current liabilities		
Trade and other payables	246,856	403,377
Employee entitlements	45,317	41,241
Total current liabilities	292,173	444,618
Total liabilities	292,173	444,618
Net assets	13,212,354	13,475,343
EQUITY		
Contributed equity	9 16,941,392	16,941,392
Other reserves	10 336,920	197,624
Retained earnings	(4,065,958)	(3,663,673)
Total equity	13,212,354	13,475,343

The above consolidated balance sheet should be read in conjunction with the accompanying notes.

Anatara Lifesciences Ltd
Consolidated statement of changes in equity
For the half-year 31 December 2016

	Share capital \$	Share-based payment reserve \$	Accumulated losses \$	Total \$
Balance at 1 July 2015	8,420,555	-	(2,939,739)	5,480,816
Loss for the period	-	-	(1,179,181)	(1,179,181)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs and tax	8,999,810	-	-	8,999,810
Capital raising cost	(582,768)	-	-	(582,768)
Share-based payment expense	-	91,107	-	91,107
Options Issues	42,750	(17,750)	-	25,000
Balance at 31 December 2015	16,880,347	73,357	(4,118,920)	12,834,784
Balance at 1 July 2016	16,941,392	197,624	(3,663,673)	13,475,343
Loss for the period	-	-	(402,285)	(402,285)
Transactions with owners in their capacity as owners:				
Share-based payment expense	-	139,296	-	139,296
Balance at 31 December 2016	16,941,392	336,920	(4,065,958)	13,212,354

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Anatara Lifesciences Ltd
 Consolidated statement of cash flows
 For the half-year 31 December 2016

	31 December 2016	31 December 2015
Notes	\$	\$
Payments to suppliers and employees	(2,633,219)	(1,443,359)
Interest received	166,423	119,879
Research and development concessions grant	420,459	165,246
Net cash inflow (outflow) from operating activities	(2,046,337)	(1,158,234)
Cash flows from investing activities		
Payments for purchases of plant and equipment	(9,420)	-
Withdrawal/(investment) from/(in) term deposits	1,582,209	(5,300,000)
Net cash inflow (outflow) from investing activities	1,572,789	(5,300,000)
Cash flows from financing activities		
Proceeds from issues of securities	-	9,024,810
Capital raising costs	-	(582,768)
Net cash inflow from financing activities	-	8,442,042
Net (decrease) increase in cash and cash equivalents	(473,548)	1,983,808
Cash and cash equivalents at the beginning of the financial year	6,387,041	1,497,539
Cash and cash equivalents at end of period	5,913,493	3,481,347

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

For personal use only

Anatara Lifesciences Ltd
Notes to the consolidated financial statements
For the half year 31 December 2016

1 Nature of operations

Anatara Lifesciences Ltd and its controlled entity ('the Group') principal activities are to develop oral solutions for gastro-intestinal diseases in animals and in humans.

2 General information and basis of preparation

Anatara Lifesciences Ltd listed on the Australian Securities Exchange on 16 October 2014.

The condensed interim consolidated financial statements (the interim financial statements) of the Group are for the six months ended 31 December 2016 and are presented in Australian dollars (\$), which is the functional currency of the parent company. These general purpose interim financial statements have been prepared in accordance with the requirements of Corporations Act 2001 and AASB 134 Interim Financial Reporting. They do not include all of the information required in annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2016 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Securities Exchange Listing Rules and the Corporations Act 2001.

The interim financial statements have been approved and authorised for issue by the board of directors on xx February 2017.

3 Estimates

When preparing the interim financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgements, estimates and assumptions applied in the interim financial statements, including the key sources of estimation uncertainty were the same as those applied in the Group's last annual financial statements for the year ended 30 June 2016.

4 Significant accounting policies

The interim financial statements have been prepared in accordance with the accounting policies adopted in the Group's last annual financial statements for the year ended 30 June 2016.

5 Segment reporting

Identification and measurement of segments - The Group uses the "management approach" to the identification, measurement and disclosure of operating segments. The "management approach" requires that operating segments be identified on the basis of internal reports that are regularly reviewed by the entity's chief operating decision maker (comprising the Board of Directors), for the purpose of allocating resources and assessing performance.

6 Reclassification of comparatives

In the preparation of the interim consolidated financial statements for the half year 31 December 2016, the Group has reclassified and recategorised its Expenses from operating activities on the Consolidated statement of profit or loss and other comprehensive income for the corresponding half year 31 December 2015. The reclassification does not result in any changes to the total Expenses, or to the net loss for the period. Details of the reclassification are provided as follows:

6 Reclassification of comparatives (continued)

	Per previously issued interim report	Reclassification adjustments	Adjusted comparatives
Expenses from operating activities			
Research and development expenses	(178,763)	(160,000)	(338,763)
Patent expenses	(73,178)	-	(73,178)
Consultancy expenses	(337,303)	(426)	(337,729)
Staff expenses	-	(500,058)	(500,058)
Employee benefit and director expenses	(640,857)	640,857	-
Travel and accommodation	(149,351)	19,200	(130,151)
ASX and share registry fees		(55,928)	(55,928)
Other expenses	(126,741)	56,355	(70,386)
Total	(1,506,193)	-	(1,506,193)

7 Revenue

	31 December 2016 \$	31 December 2015 \$
Revenue		
Interest received	<u>166,423</u>	161,766
Other income		
Other income - R&D tax incentive	<u>1,936,105</u>	165,246

8 Loss per share

Both the basic and diluted loss per share have been calculated using the profit attributable to shareholders of Anatara as the numerator, i.e. no adjustments to profits were necessary during the six months period to 31 December 2016 and 2015.

The weighted average number of shares for the purposes of the calculation of diluted loss per share has not been adjusted, as share options on issue are antidilutive.

(a) Basic loss per share

	31 December 2016 Cents	31 December 2015 Cents
Basic loss per share	(0.81)	(2.76)
Diluted loss per share	(0.81)	(2.76)

(b) Reconciliation of loss used in calculating earnings per share

	31 December 2016 \$	31 December 2015 \$
Profit attributable to the ordinary equity holders of the Company used in calculating basic earnings per share:		
Net loss used in the calculation of basic and diluted loss per share	<u>(402,285)</u>	(1,179,181)

8 Loss per share (continued)

(c) Weighted average number of shares used as denominator

	31 December 2016 Number	31 December 2015 Number
Weighted average number of ordinary shares used as the denominator in calculating basic loss per share	<u>49,413,236</u>	<u>42,786,613</u>

9 Contributed equity

(a) Share capital

	31 December 2016 Shares	30 June 2016 Shares	31 December 2016 \$	30 June 2016 \$
Ordinary shares				
Ordinary shares - fully paid	49,413,236	49,413,236	16,941,392	16,941,392

(b) Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held.

On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.

10 Share-based payments

	2016 Options	2016 \$
Share-based payment reserve		
Opening balance at 1 July	1,980,000	197,624
Options issued during the period	420,000	40,084
Share-based payment expenses	-	99,212
Closing balance at 31 December	<u>2,400,000</u>	<u>336,920</u>

Details of options issued during the period:

Date	Details	No.	Share-based payment expense \$
23/9/2016	Issue of options to an employee at exercise price of \$1.70 per share	210,000	20,042
23/9/2016	Issue of options to an employee at exercise price of \$1.70 per share	210,000	20,042
	Total movements	420,000	40,084

The general terms and conditions of the options were:

- No dividends or voting rights attached
- Exercise price set at a premium to share price at date of entitlement
- Subject to vesting periods
- All shares allotted upon exercise of options will upon allotment rank pari passu in all respects with other shares

Anatara Lifesciences Ltd
Notes to the consolidated financial statements
For the half year 31 December 2016
(continued)

11 Net tangible assets

	31 December 2016	31 December 2015
Net tangible assets	13,212,354	12,834,784
No. of shares	49,413,236	49,338,236
Net asset backing (per share)	0.27	0.26

12 Dividends

No dividends were declared or paid during the half year period ended 31 December 2016 (2015: Nil).

13 Events occurring after the reporting period

On 30 January 2017, the Group received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. for Detach™, Anatara's non-antibiotic anti-infective product.

No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or the state of affairs of the Group or economic entity in subsequent financial periods.

Anatara Lifesciences Ltd
Directors' declaration
31 December 2016

In the directors' opinion:

- (a) the interim financial statements and notes set out on pages 4 to 11 are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with AASB 134 *Interim Financial Reporting*, the *Corporations Regulations 2001* and other mandatory professional reporting requirements, and
 - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date, and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of directors.



Mel Bridges
Executive Chairman

Brisbane, Queensland

Dated: This the 22th Day of February 2017.

The Rialto, Level 30
525 Collins St
Melbourne Victoria 3000

Correspondence to:
GPO Box 4736
Melbourne Victoria 3001

T +61 3 8320 2222
F +61 3 8320 2200
E info.vic@au.gt.com
W www.grantthornton.com.au

Independent Auditor's Review Report To the Members of Anantara Lifesciences Ltd

We have reviewed the accompanying half-year financial report of Anantara Lifesciences Ltd ("Company"), which comprises the consolidated financial statements being the statement of financial position as at 31 December 2016, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a statement or description of accounting policies, other explanatory information and the directors' declaration of the consolidated entity, comprising both the Company and the entities it controlled at the half-year's end or from time to time during the half-year.

Directors' responsibility for the half-year financial report

The directors of Anantara Lifesciences Ltd are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such controls as the directors determine are necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the consolidated half-year financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Anantara Lifesciences Ltd consolidated entity's financial position as at 31 December 2016 and its performance for the half-year ended on that date; and complying with Australian Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Anantara Lifesciences Ltd, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

Grant Thornton Audit Pty Ltd ACN 130 913 594
a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation.

For personal use only

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Anantara Lifesciences Ltd is not in accordance with the Corporations Act 2001, including:

- a giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date; and
- b complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.



GRANT THORNTON AUDIT PTY LTD
Chartered Accountants



M. A. Cunningham
Partner – Audit & Assurance

Melbourne, 22 February 2017

For personal use only

Anatara Lifesciences Ltd
Corporate directory

Directors

Dr Melvyn Bridges
Executive Chairman

Mr Iain Ross
Non-Executive Director

Dr Jay Hetzel
Non-Executive Director

Dr Tracie Ramsdale
Non-Executive Director

Mr Paul Grujic
Non-Executive Director

Dr Paul Schober (resigned 23 September 2016)
Chief Executive Officer and Managing Director

Secretary

Mr Stephen Denaro

Principal registered office in Australia

433 Logan Road, Stones Corner,
Brisbane Queensland 4120
Australia
+61 (0)7 3831 8866

Share and debenture register

Computershare Investor Services Pty Ltd
117 Victoria Street, West End
Queensland 4101
1300 787 272 (local)

Auditor

Grant Thornton Audit Pty Ltd
The Rialto, Level 30, 525 Collins Street
Melbourne Victoria 3000
+61 (0)3 8320 2222

Solicitors

McCullough Robertson
Level 11, Central Plaza Two, 66 Eagle Street,
Brisbane Queensland 4000

Bankers

CBA
Melbourne Victoria

Securities Quoted

Australian Securities Exchange - Ordinary Fully Paid
Shares (Code: ANR)

Website

www.anataralifesciences.com

For personal use only